Literature DB >> 23529152

Minimally invasive lumbar transfacet screw fixation in the lateral decubitus position after extreme lateral interbody fusion: a technique and feasibility study.

Jean-Marc Voyadzis1, Amjad Nasr Anaizi.   

Abstract

STUDY
DESIGN: Prospective evaluation of 10 patients undergoing minimally invasive lumbar interbody fusion for degenerative disk disease and radiculopathy.
OBJECTIVE: To assess the feasibility of percutaneous lumbar transfacet screw fixation in the lateral decubitus position after lateral interbody fusion. SUMMARY OF BACKGROUND DATA: Lumbar interbody fusion is commonly performed for the treatment of degenerative disk disease with associated radiculopathy due to foraminal stenosis or disk protrusion. Minimally invasive techniques, such as the lateral interbody fusion, have been developed to achieve this while reducing operative morbidity. Subsequent vertebral fixation is best achieved with a pedicle screw and rod construct in the prone position. Transfacet screw placement has been shown to have near biomechanical equivalence and may reduce operative time and morbidity if placed while the patient remains in the lateral decubitus position.
METHODS: Ten patients with back pain and radicular pain due to single-level degenerative disk disease at L3-L4 or L4-L5 underwent minimally invasive lateral interbody arthrodesis with placement of bilateral percutaneous transfacet screws in the lateral decubitus position. Patients had close perioperative follow-up including recordings of intraoperative blood loss, operative time, and hospital length of stay. Clinical outcome measures including visual analog scores (VAS) were assessed preoperatively and at last follow-up with a minimum of 6 months. Dynamic radiographs were obtained at last follow-up to evaluate the instrumentation and fusion rate.
RESULTS: The procedure was well tolerated by all patients. Mean operative time was 2 hours and 42 minutes. Mean blood loss was 26.5 mL. Mean hospital length of stay was 46.5 hours. Nine of 10 patients had good-to-excellent relief of their preoperative back pain and leg pain. Mean preoperative VAS score for back pain was 8.9 and for leg pain was 8. At a mean follow-up of 8.2 months, mean postoperative VAS score for back pain was 0.9 and for leg pain was 0.9. There were no complications. One patient suffered persistent mild leg dysesthesias. There were no instances of graft or screw dislodgement on follow-up imaging.
CONCLUSIONS: Minimally invasive percutaneous transfacet screw fixation can be performed safely and effectively in the lateral decubitus position. This is an attractive option for posterior percutaneous fixation that can lead to a reduction of operative time and surgical morbidity in select cases.

Entities:  

Mesh:

Year:  2013        PMID: 23529152     DOI: 10.1097/BSD.0b013e318241f6c3

Source DB:  PubMed          Journal:  J Spinal Disord Tech        ISSN: 1536-0652


  4 in total

1.  CT-Guided Transfacet Pedicle Screw Fixation in Facet Joint Syndrome: A Novel Approach.

Authors:  Luigi Manfré
Journal:  Interv Neuroradiol       Date:  2014-10-17       Impact factor: 1.610

2.  Prospective evaluation of 1-year outcomes in single-level percutaneous lumbar transfacet screw fixation in the lateral decubitus position following lateral transpsoas interbody fusion.

Authors:  Jay W Rhee; Rory J Petteys; Amjad N Anaizi; Faheem A Sandhu; Jean-Marc Voyadzis
Journal:  Eur Spine J       Date:  2015-04-18       Impact factor: 3.134

Review 3.  MIS lateral spine surgery: a systematic literature review of complications, outcomes, and economics.

Authors:  Jeff A Lehmen; Edward J Gerber
Journal:  Eur Spine J       Date:  2015-04-08       Impact factor: 3.134

Review 4.  Single-position circumferential lumbar spinal fusion: an overview of terminology, concepts, rationale and the current evidence base.

Authors:  J Alex Thomas; Cristiano Menezes; Aaron J Buckland; Kaveh Khajavi; Kimberly Ashayeri; Brett A Braly; Brian Kwon; Ivan Cheng; Pedro Berjano
Journal:  Eur Spine J       Date:  2022-08-01       Impact factor: 2.721

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.